Selection of in vitro mutants of pyrazinamide-resistant Mycobacterium tuberculosis

International Journal of Antimicrobial Agents

Volumn 20, Issue 4, 2002, Pages 275-281

  Bamaga, M ^a   Wright, D J M ^a   Zhang, H ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Antimicrobial resistance; BACTEC; pncA Mutation; Pyrazinamidase; Pyrazinamide

Indexed keywords

BACTERIAL ENZYME; PYRAZINAMIDASE; PYRAZINAMIDE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG EXPOSURE; ENZYME ACTIVITY; FRAMESHIFT MUTATION; GENE; GENE DELETION; GENE LOCATION; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; RADIOMETRY; SEQUENCE ANALYSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 0036774971     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00182-6     Document Type: Article

References (27)

1. Aquinas M. Short-course therapy for tuberculosis. Drugs. 24:1982;118-132.
2. Sun Z., Scorpio A., Zhang Y. The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms. Microbiology. 143:1997;3367-3373.
3. Zhang Y., Scorpio A., Nikaido H., Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:1999;2044-2049.
4. Cheng S.J., Thibert L., Sanchez T., Heifets L., Zhang Y. pncA Mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Que., Canada. Antimicrob. Agents Chemother. 44:2000;528-532.
5. Heifets L.B., Flory M.A., Lindholm-Levy P.J. Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? Antimicrob. Agents Chemother. 33:1989;1252-1254.
6. Zimhony O., Cox J.S., Welch J.T., Vilcheze C., Jacobs W.R. Jr. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6:2000;1043-1047.
7. Hirano K., Takahashi M., Kazumi Y., Fukasawa Y., Abe C. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber Lung Dis. 78:1997;117-122.
8. Morlock G.P., Crawford J.T., Butler W.R., et al. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44:2000;2291-2295.
9. Scorpio A., Lindholm-Levy P., Heifets L., et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 41:1997;540-543.
10. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:1996;662-667.
11. Sachais B.S., Nachamkindagger I.I., Mills J.K., Leonard D.G. Novel pncA mutations in pyrazinamide-resistant isolates of Mycobacterium tuberculosis. Mol. Diagn. 3:1998;229-231.
12. Lemaitre N., Sougakoff W., Truffot-Pernot C., Jarlier V. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob. Agents Chemother. 43:1999;1761-1763.
13. Mestdagh M., Fonteyne P.A., Realini L., et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 43:1999;2317-2319.
14. Hou L., Osei-Hyiaman D., Zhang Z., Wang B., Yang A., Kano K. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol. Infect. 124:2000;227-232.
15. Mestdagh M., Realini L., Fonteyne P.A., et al. Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 Mycobacterium tuberculosis clinical isolates. Microb. Drug Resist. 6:2000;283-287.
16. Hannan M.M., Desmond E.P., Morlock G.P., Mazurek G.H., Crawford J.T. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J. Clin. Microbiol. 39:2001;647-650.
17. Peloquin C.A., Jaresko G.S., Yong C.L., Keung A.C., Bulpitt A.E., Jelliffe R.W. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:1997;2670-2679.
18. Conte J.E. Jr, Golden J.A., Duncan S., McKenna E., Zurlinden E. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43:1999;1329-1333.
19. Wayne L.G. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis. 109:1974;147-151.
20. Ausubel F.M., Brent R., Kingston R.E., et al. Current protocols in molecular biology. 1994;Wiley, New York.
21. Rinder H., Mieskes K.T., Loscher T. Heteroresistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 5:2001;339-345.
22. Kim B.J., Kim S.Y., Park B.H., et al. Mutations in the rpoB gene of Mycobacterium tuberculosis that interfere with PCR-single-strand conformation polymorphism analysis for rifampin susceptibility testing. J. Clin. Microbiol. 35:1997;492-494.
23. Pastor A., Peman J., Canton E. In-vitro postantibiotic effect of sparfloxacin and ciprofloxacin against Pseudomonas aeruginosa and Enterococcus faecalis. J. Antimicrob. Chemother. 34:1994;679-685.
24. Klemens S.P., Sharpe C.A., Cynamon M.H. Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility. Antimicrob. Agents Chemother. 40:1996;14-16.
25. Marttila H.J., Marjamaki M., Vyshnevskaya E., et al. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwestern Russia. Antimicrob. Agents Chemother. 43:1999;1764-1766.
26. Sreevatsan S., Pan X., Zhang Y., Kreiswirth B.N., Musser J.M. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. Antimicrob. Agents Chemother. 41:1997;636-640.
27. Boshoff H.I., Mizrahi V. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J. Bacteriol. 182:2000;5479-5485.